Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 17,100 shares, a decrease of 17.4% from the March 15th total of 20,700 shares. Based on an average trading volume of 28,700 shares, the short-interest ratio is currently 0.6 days. Currently, 0.4% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ASMB. Peapod Lane Capital LLC purchased a new position in Assembly Biosciences during the fourth quarter worth about $994,000. JPMorgan Chase & Co. grew its position in Assembly Biosciences by 5,137.3% in the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares during the period. FMR LLC increased its stake in Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares during the last quarter. Monimus Capital Management LP purchased a new stake in Assembly Biosciences in the fourth quarter valued at $664,000. Finally, Palumbo Wealth Management LLC acquired a new position in shares of Assembly Biosciences in the 4th quarter valued at $180,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Trading Up 0.2 %

Shares of NASDAQ ASMB opened at $10.03 on Friday. The company has a 50-day moving average of $10.88 and a 200 day moving average of $14.05. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $19.93. The stock has a market cap of $75.26 million, a PE ratio of -1.49 and a beta of 0.65.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) EPS for the quarter, beating the consensus estimate of ($1.75) by $0.18. The firm had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. On average, sell-side analysts forecast that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ASMB. StockNews.com cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, March 24th. Finally, Guggenheim began coverage on Assembly Biosciences in a research report on Tuesday, March 25th. They set a “buy” rating and a $31.00 price target for the company.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.